

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **CSPC PHARMACEUTICAL GROUP LIMITED**

**石藥集團有限公司**

*(Incorporated in Hong Kong with limited liability)*

**(Stock Code: 1093)**

### **VOLUNTARY ANNOUNCEMENT**

#### **A SELECTIVE 5-HT<sub>2A</sub> RECEPTOR AGONIST (SYH2056 TABLETS) OBTAINS CLINICAL TRIAL APPROVAL IN THE U.S.**

The Board of Directors (the “**Board**”) of CSPC Pharmaceutical Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) is pleased to announce that a selective 5-hydroxytryptamine 2A receptor (“**5-HT<sub>2A</sub> receptor**”) agonist (SYH2056 tablets) (the “**Product**”), a Class 1 new chemical drug developed by the Group, has obtained approval from the U.S. Food and Drug Administration to conduct clinical trials in the U.S. The Product also obtained approval from the National Medical Products Administration of the People’s Republic of China in November 2025 to conduct clinical trials in China.

The Product is a selective 5-HT<sub>2A</sub> receptor agonist that improves the disease state of patients with depressive disorders by activating this receptor. A single administration produces a rapid onset of action with a long-lasting effect and without hallucination risk. The indication for this clinical trial approval is for the treatment of major depressive disorder. Preclinical studies showed that the Product could effectively promote the formation of dendrites and dendritic spines in central neurons and had a facilitating effect on neural remodeling. In multiple animal models of depression, the Product demonstrated excellent antidepressant activity while significantly reducing the potential hallucination risk associated with this target. At the same time, it also exhibited favorable pharmacokinetic (PK) characteristics and safety, giving it the potential to become a best-in-class antidepressant. Currently, the Group has submitted multiple patent applications for the Product both domestically and internationally.

Given the many insurmountable clinical limitations of traditional antidepressants and the lack of therapies with novel mechanisms for depressive disorders, there is a broad clinical demand for the Product, providing a promising clinical development value.

By order of the Board  
**CSPC Pharmaceutical Group Limited**  
**CAI Dong Chen**  
*Chairman*

Hong Kong, 3 December 2025

*As at the date of this announcement, the Board comprises Mr. CAI Dong Chen, Mr. ZHANG Cuilong, Mr. WANG Zhenguo, Mr. WANG Huaiyu, Dr. LI Chunlei, Dr. YAO Bing, Mr. CAI Xin, Mr. CHEN Weiping and Mr. QU Zhiyong as Executive Directors; and Mr. WANG Bo, Mr. CHEN Chuan, Prof. WANG Hongguang, Mr. AU Chun Kwok Alan, Mr. LAW Cheuk Kin Stephen and Ms. LI Quan as Independent Non-executive Directors.*